KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $128.2 million.

  • West Pharmaceutical Services' Net Income towards Common Stockholders rose 7.81% to $128.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $479.3 million, marking a year-over-year increase of 27.2%. This contributed to the annual value of $479.3 million for FY2025, which is 27.2% up from last year.
  • As of Q4 2025, West Pharmaceutical Services' Net Income towards Common Stockholders stood at $128.2 million, which was up 7.81% from $137.9 million recorded in Q3 2025.
  • Over the past 5 years, West Pharmaceutical Services' Net Income towards Common Stockholders peaked at $183.0 million during Q2 2022, and registered a low of $86.4 million during Q1 2025.
  • In the last 5 years, West Pharmaceutical Services' Net Income towards Common Stockholders had a median value of $134.0 million in 2023 and averaged $137.0 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 12075.72% in 2021, then crashed by 3243.06% in 2022.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' Net Income towards Common Stockholders stood at $147.7 million in 2021, then crashed by 32.43% to $99.8 million in 2022, then skyrocketed by 33.97% to $133.7 million in 2023, then fell by 4.19% to $128.1 million in 2024, then increased by 0.08% to $128.2 million in 2025.
  • Its last three reported values are $128.2 million in Q4 2025, $137.9 million for Q3 2025, and $126.8 million during Q2 2025.